Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7300490 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation (RO7300490 Monotherapy) | EXPERIMENTAL | Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent. |
| Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy) | EXPERIMENTAL | Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent. |
| Part 3: Dose Expansion (Disease-specific Expansion(s)) | EXPERIMENTAL | Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| RO7300490 | DRUG | Participants will receive RO7300490, as described in the Arm Descriptions. |
| Atezolizumab | DRUG | Participants will receive Atezolizumab, as described in the Arm Descriptions. |
Inclusion Criteria: * Life expectancy of \>= 12 weeks. * Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors that are not amenable to standard therapy. * Radiologically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * A...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
RO7300490 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being evaluated as a single agent and in combination with atezolizumab in participants with advanced solid tumors.
RO7300490 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research to evaluate the safety, pharmacokinetics, and anti-tumor activity of this investigational drug.
RO7300490 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed to evaluate its safety and tolerability.
RO7300490 has been studied in one clinical trial, identified as NCT04857138. This Phase 1 study evaluated the drug as a single agent or in combination with atezolizumab in participants with advanced solid tumors. The trial has been completed.
No, RO7300490 is not the same as atezolizumab. RO7300490 is an investigational small molecule, while atezolizumab is a separate drug that was used in combination with RO7300490 in the clinical trial. They are distinct therapeutic agents.